Liquid Chromatographic-MS/ MS Determination of Atorvastatin and Metabolites in Human Plasma
 
More details
Hide details
1
K. B. Institute of Pharmaceutical Education and Research. Sector 23, Gandhinagar 382023
2
Synchron Research Pvt Ltd. “The Chambers” S.G.Highway, Ahmedabad. 380051
3
L. M. College of Pharmacy, Navrangpura, Ahmedabad-380009
CORRESPONDING AUTHOR
Ashutosh J. Jani   

K. B. Institute of Pharmaceutical Education and Research. Sector 23, Gandhinagar 382023
Publish date: 2017-10-05
 
Eurasian J Anal Chem 2010;5(1):46–52
KEYWORDS
ABSTRACT
The aim of the present study was to develop a chromatographic method for the analysis of atorvastatin, Ortho- and Para -hydroxyatorvastatin in human plasma after administration of atorvastatin at the dose of 40 mg in clinical studies. Sample preparation was performed by solid phase extraction and was followed by separation of the analytes on an HPLC system with a linear gradient and a mobile phase consisting of acetonitrile, water and formic acid. Detection was achieved by tandem mass spectrometry operated in the electrospray positive ion mode. Validation of the method for the compounds for which reference compounds were available (acid forms of atorvastatin, o- and p-hydroxyatorvastatin) showed linearity within the concentration range for atorvastatin acid 0.2–40 ng/ml, Para-hydroxyatorvastatin acid 0.250-50 ng/ml, and ortho-Hydroxyatorvastatin acid 0.25–50 ng/ml (r2>0.99, n=3 for all analytes). Accuracy and precision (evaluated at 0.5, 17 and 31 ng/ml for atorvastatin, 0.66, 22, 40 ng/ml for Para--hydroxyatorvastatin and ortho-hydroxyatorvastatin) were both satisfactory. The detection limit was 0.06 ng/ml for atorvastatin and para -hydroxyatorvastatin, and 0.15 ng/ml for ortho -hydroxyatorvastatin. The method has been successfully applied in a clinical study where atorvastatin, o- and para - hydroxyatorvastatin could be detected in a 24-h sampling interval after administration of registered dose of atorvastatin (40 mg) for one week.
 
REFERENCES (9)
1.
Parke-Davis (2004) Product information: Lipitor (Atorvastatin Calcium). Parke-Davis (Division of Pfizer Inc.), Ann Arbor, MI.
 
2.
Asberg A, Hartmann A, Fjeldsa E, Bergan S, Holdaas H. (2001) Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant. 1(4):382.
 
3.
Amsden GW, Kuye O, Wei GC (2002) A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J Clin Pharmacol. 42(4): 444.
 
4.
Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM. (2001) Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother. 45(12): 3445.
 
5.
Siedlik PH, Olson SC, Yang BB, Stern RH (1999) Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol. 39(5): 501.
 
6.
Bullen WW, Miller RA, Hayes RN.(1999) Development and validation of a highperformance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma. J Am Soc Mass Spectrom. 10(1): 55.
 
7.
Jemal, M.; Ouyang, Z.; Chen, B.-C.; Teitz, D.(1999) Quantitation of the Acid and Lactone Forms of Atorvastatin and its Biotransformation Products in Human Serum by High-Performance Liquid Chromatography with Electrospray Tandem Mass Spectrometry. Rapid Communications in Mass Spectrometry 13:1003.
 
8.
Kantola T, Kivisto KT, Neuvonen PJ (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther. Jul;64(1):58.
 
9.
Lins RL, Matthys KE, Verpooten GA, Peeters PC, Dratwa M, Stolear JC, Lameire NH. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients.(2003) Nephrol Dial Transplant. 18(5): 967.
 
eISSN:1306-3057